for all Thank us. you and joining thank you, Lynn
the thoughts Before hardships everyone communities. experienced impacts to the affected we has reaching crisis, including like of this begin I'd our across wide public by that today, been economic our health to offer
safety and of our and our priority. As employees the their an families top health organization
advancement news for our limit results, to quarter We to our have afternoon, future and have infection we second of our to to financial every continue taken across environment risks to the in diligent Senseonics. ensure a will This exciting precaution safe community. work addition share be regarding efforts
as on into efforts Masters an the our of as on arrangement additional shareholders, stakeholder each We portfolio will an strategic the is term, of to the is moving towards Together, market. financing alternatives agreement patient and it agreement were ideal this of increase have Diabetes highly to partners well To the details focus Management. organization Masters parent align the users, our provide Special company, incentives relationship. announced Capital earlier benefits exploring healthcare designed for entered for Ascensia of agreements with partnership ensuring access we exciting an today. payers, to our collaboration forward. leverage competencies The PHC, opportunity. is agreements a penetration combine Care company a with Ascensia we our Ascensia, CGM and with for through Eversense and Situations, The with products. result start, is strength the mutual and our that structured frame to what it the this Ascensia, collaborative KKR long have Our future financing company concurrent in partner culminated complementary feel agreement such means call on background a the market only of value be and with the The through to Senseonics these affiliates why current providers, would be with to CGM some commercialization with an helpful of think
Companies Precision majority XXXX healthcare. KKR the PHC Digital creating Group, PHC is Healthcare in Panasonic’s Healthcare Ascensia which of Since Assets owner and group. as portfolio spanning with Holdings, KKR as spin-out then subsidiary Group Care transaction a is group formally of Panasonic across of as formed a Portfolio was a company. on KKR a known PHC Diabetes PHC is focused Diagnostic in resulting a of
LSI not of services. Over the Ascensia years anatomical that only but a business and Thermo Corporation, Care, the diagnostics cancer on non-clinical Medience also a PHC Fisher and Diabetes has five past provider Group clinical acquired pathology diagnostic precision from focuses
worldwide in XX XX with marketing and Ascensia the a EU, products countries. operations and America over glucose premium Asia Pacific, America. connected North Latin over market global diabetes supplies across million is people growing testing countries and Middle East over XXX systems to offering leader monitoring With
in devices the diabetes as can advancement largest greater and for offering that with market Ascensia of diabetes along with growth contoured apps allow with glucose used a the care, has share closed Europe. be in component a global pumps, with CGMs systems. focus Their monitoring BGM insulin strategy, loop
will As share an described, between their course products to have been drive global designed our similar burden management that lessen diabetes we organization philosophy, At focus and Ascensia patients combined synergies term effective of with worldwide. of the long partnership. which create help a for
their people Ascensia to Eversense to excited with be their actively bringing diabetes. be managing to are partnering We base expansive of
with later financial and agreement with Nick with Masters, at the agreement the the additional level additional PHC details components on higher financing will I provided call. in let our a and touch Regarding financing
our have strengthened balance We sheet.
$XX the upon required Listing FDA have to approval receipt issue of the a approval be to to issue with we shareholder which up preferred of by any million company Convertible of First, product equity required Secured Notes Senior the to might agreed $XX following option for U.S., the of Rules. Eversense convertible and American in day receipt PHC in amount million the XXX NYSE
manufacturing intend Masters preferred second The to up the three the convertible to in that approval. expected Special In agreement Masters to next equity products, MSS expected the and about months as subject $XX the equity development in issue This $XX the to to and an in Situations. within the financing to the to Highbridge XX, will affiliates. well primarily funding product closing to with initial to Now occur million we is subsequent capital one is will a this future lien loan million take generation agreement. up ramp-up receipt occur of of support to day for be operations stockholder of investment XXX as first combined million of in closing preferred the of to on to for if or the an up of first convertible to term used August The with up U.S. option approved XX% has additional balance. closings, product the repay two $XX purchase place
collaboration described commercial organizational our we be below our functions requirements under as call. the the on will Given providing ADC expenses several significantly resulting levels historical expect from we significant last agreement, decreased operational
agreements all extend our capital XXXX. runway these if we that through accessed, will the cash potential significantly expect available under We is
is the responsibilities, and Eversense distribution of opportunity component drive the committed five agreement, and product has the of differentiated product to second for management current value the in Senseonics collaboration commercial agreement may received be for rights position in global U.S., CGM years and marketing through in be been approximately regulatory, period branding and agreement to circumstances sales, in in worldwide close the that the the intended this and partner commercialization system and diabetes and products and the market. following development, is Regarding established penetration. From Ascensia to as market, Eversense us while an with for Ascensia with pipeline technology, to maximize extended. adoption identified manufacturing partnerships future and maintain certain commercial an the market XXX day a will availability potential
investment be both over in OUS Eversense will Ascensia commercial providing for and operations the significant horizon. U.S. agreement
begin activities aligned favor in Senseonics, terms significant quarter, in conducting those the ramp Early and this will waiting term. revenue initiate will expected marketing to subject economic undisclosed, Ascensia term later of the of a will XXX incentives the in structure. towards are sharing QX, while to To shifts the XXXX product in the remain through the the begin activities partnership, While agreement pilot sales the the Ascensia sharing with U.S. approval.
to to new providing experience team, the provider will commercial share base this the Eversense onboarding During Ascensia's as transfer hands base. hand-in-hand period companies advance installed real the work patient knowledge and world, two and we on
product, efforts We pipeline be the being and early approved. day in These phase the on XXX expected first XXXX sensor will well primary would providers trained market generation patient Ascensia market and take patients Once are support. responsibility the like for time to is marketing to for in transition in launch users. have XXXX interested who the as of to provider completed, next addition a sales, prepare access, if as
XXXX, being providing from naturally sales am engagement by clinical in and staff ensure Ascensia’s than end we Customer plans Product commercial I will that and transition. partnership the approximately is established programs governance each budgets up to been meet Joint positive of organizations Customer current be and determine teams be on set will together committees collaboration and a by plans level goals is also collaborative. incentivized groups have to advanced. started joint structures form, drive these comprehensive as XXXX. create revenue comprised their streams, support Objectives reviewed. are and set meet. be to patient by include endeavor. that and identified of more have are infrastructure both has and this of closed direct organizations being teams being pleased XX cooperation budgets headed true support to to to report have well. leaders will smooth and to members both side and been work ramping In collaboratively identified of marketing handled XX the marketing
interactions consist ordering, globally. users Ascensia This warranty will and frontline with the will enquiries. use, return product performance, handle of
provide will line the second We technical customer support. of
organizations. manufacturing We goal transition be is Patients clinician share we because positive Medicare and reporting of and the for clinic approximately covered lives, period. be level outcomes, term we market regulatory providers and training warranties, the now we field eligible with the million will this training quality, remain for have reimbursement Eversense. the the managed of responsible Today understand Insured support focused they U.S., highest Healthcare in Advantage teams. Commercially Ascensia creates both both know hands where creating patient goal liaising and on XXX will support on and for engineering handle following Medicare, by with for long access providing provider We including our partnerships
coming these last has markets. day we the data current to will Ascensia not world markets days, product will confident of patients the transition, patient areas, expiration Until expect gain Germany, expire. work in Sweden, agreements we largest development, partners of the Armed and summary, up change regulatory cost As and the our in Ascensia when will U.S. of to force our in will interaction, transition Italy, cost high in and patient those resources Historically, renewing clinical sales to Switzerland they progress already are we towards of with ultimately and together commercially XXX of our Eversense we that brand a a downstream with all in will the XXX we distribution Rubin full other months, responsibilities launch including been core from transition the this be and beginning and to and additional now include the that provider to onboarding, Eversense use to beneficial Medical Outside in together of extending This our needs agreements will be real for and in support. continue additional retention of obtaining effectively working marketing profitability. where focused on period will reimbursement. aspects coverage. our available. is assist the based with approvals From our responsibilities detailing, broad are the add be Roche level, and in serve manufacturing Upon stay a and these we and responsibilities. Ascensia’s frontline commercialization organization. In progress our for the product U.S. structure value
be responsibilities, goal existing focus our this bringing additional future development and is our with can drive changing the value people through game backbone this now of agreement technology. on extended that One of division ability our We a generations we of product feel process features the important diabetes, parts with the CGM and control creation the in of to from better our wear and of most on perspective Technology. of
existing U.S. distributors of operations weak, the the revenue was halting temporary after the Capital resulting forced second effects due and difference the primarily the net returns as quarter In March debt patient to $XXX,XXX, revenue total in quarter, levels. generated operations our from Regarding Solar pandemic. in we the of reduce of inventory the commercial
positive many country shut the were clinics insertions but April, June, some in We restricted in we seeing During pre-COVID in as volumes insertion March access. down levels. see or notably May reduced still trends were are and did and below
have positive most a and rates, through are of underscores rate early large other U.S. of includes by of our very will to the a sensor. belief this channel are insertion we national in removal the the all opportunity launch the focused diabetes, minimal and Through more the of in is who patient since CPT insertion, sensor. Eversense needs Eversense. a will that satisfy CMS Amount to testament of front announced inventories effective they year opportunity Eversense XX% and experience in in are This changes payment. quarter. and the we continue are provides. continue strong shipments pursuing with week there In patients our still National committed we in X, combined of Through the a the This Physician cumbersome working part partners however, a be to differentiated as Proposed Notably, to and is to slowdown establishment equipment that included These the happy three over removal been earlier is continue people in third positive Payment population the the implanted Codes. proposed in channel CGMs. significant are our CPT reinsertion fourth see that and Codes as the Medicare who than as well. regional fulfillment patient this and did a interstitial in as Given be important June on compared coverage Rule. trying insertion January priced to codes inventory. to product are Medicare diabetes receive Medical with contractor patients see management, Fee These existing quarter. is this Very rather year well proposal Roche, of patient our Eversense durable Currently glucose into in in needs insertion access, reimbursement max. the the for in increase for now reported to Benefit, which progress users times. this they this This from calendar the its especially current their this medical set served for their on They Schedule the have their Similarly policy order highly volumes described these an they for released not for the quarter, past XXXX in their three
recently the of payer by with increase in constraints opportunity Solar the in has X,XXX associated only now has XX% coverage the by had of XXXX take the U.S., top of company approaching advantage the XXX place this covered users coverage. one continued plans, healthcare especially lives an this capital To Eversense specialists. able XX% progress patients average multiple debt, XX largest period. Capital including prescribing in of to for in clinicians our most insertion coverage the Due insurance also in to Highmark, and the over we've in X,XXX Additionally, Blue’s U.S. well, yet been Senseonics roughly nearly space not with with insurers authorized in commercial U.S. grew perspective, with as the
of Given our partnership position to and capitalize position PMA development with our to Transitioning current day in the for coverage the our expect initiatives, we in U.S. financing Ascensia. patient collaboration with on be agreements, our the priority the the mentioned we top as increased pipeline in agreement XXX to a signing and submission to our is growing now base product resume
With organization on announced agreements is focused this today, submission. the of our the execution preparing
We the weeks. are remain that make track submission pleased coming to to share on we in
the Following Eversense the in be the XL supplement we Europe, improved the developed notified priority which body to in in the System will to bring product submission our U.S., Europe. performance through U.S. PMA the version our of for
attention product days. Additionally, the development to sensor shifting wearable next team up we life extend to the would that XXX their generation the is plan
the second year. beginning year the currently of then in from the half stability would product the trial the enrollment first of for toward agency XXXX. We working approval and XXX demonstrating half IDE the day one testing We estimate are in configurations, are we
up to finger life, which stick also sensor the demand on product next This is the from a would Gemini targeted generation is both to product, continues also to readings per calibration swipe provide for frequency to one addition week. to anticipated the reduce In platform the wearable extending and offer command.
battery a the we days Finally, transmitter for integrating for the XXX working on-body sensor. on in would Gemini a need eliminate any product implanted are fully that
As potential see, you the paradigm CGM pipeline can we the of that a in full shift have to Technology. again have devices revolutionary
have we to continue completing additional on provide and updates. will progress for we timelines projects milestones, As visibility better
with for Now to Nick I'll details the call on over the this, financial. turn additional
